Highly concentrated aqueous protein solution with reduced viscosity

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Adocia patent solves the following problem:

Our analysis of this patent is as follows:

Adocia’s patent US 9457089 B2 deals with Highly concentrated aqueous protein solution with reduced viscosity.
In an aqueous solution, a composition includes at least one protein, including at least one antibody fragments, and at least one water-soluble viscosity-reducing agent selected from the group consisting of cytidine, 2-deoxycytidine, uridine, 2-deoxyuridine, thymidine and ribothymidine, alone or as a mixture. proteins include at least one antibody fragment in a concentration greater than or equal to 50 mg / ml.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Container for the generation of therapeutic microfoam

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Btg International Limited patent solves the following problem:

Sclerosis of varicose veins is based on vein injection of liquid sclerosant substances which, by inter alia causing a localized inflammatory reaction, favor the elimination of these abnormal veins. Until recently, sclerotherapy was a technique selected in cases of small and medium caliber varicose veins, those with diameters equal to or greater than 7 mm being treated by surgery. Sclerotherapy and operation nagkakomplimento one another, but to treat with sclerotherapy continues to apply to large varicose veins. In these large varicose veins, if a sclerosing liquid is injected, the amount of liquid sclerosant necessary to fill the entire length of the varicose vein exceeded safe limits dose to normal sclerosant concentration, and may be effective concentration needed to limit the dose to safe levels. Furthermore, its concentration in the vein, the uniform distribution of blood, and the period for which it is in contact with the internal walls of the vessel treated were not known.

Our analysis of this patent is as follows:

Btg International Limited’s patent US 9457160 B2 deals with Container for the generation of therapeutic microfoam.
Device containing sclerosant liquid for use in the treatment of blood vessels with an aerosol valve housing containing a gas entry port. The aerosol valve housing sitting in a canister containing an expandable inner vessel which sclerosant fluid available. The expandable container affixed to the outer opening of the canister or aerosol valve housing on the gas valve port-entry to gas taken from within the expandable container can mix with sclerosant liquid to make a micro bubbles, so that the introduction of pressurized gas through the aerosol valve causing expandable container to inflate to accommodate the pressurized gas.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Abrasion resistant glove

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Ansell Healthcare Products Llc patent solves the following problem:

Our analysis of this patent is as follows:

Ansell Healthcare Products Llc’s patent US 9456645 B2 deals with Abrasion resistant glove.
A glove comprising an elastomeric coating with a particle filler and a way to make such a glove. In particular, the glove is made of a knitted liner formed from at least one thread; an elastomeric coating that covers at least a portion of the knitted liner; and wherein the elastomeric coating comprises a filler particle having a hardness greater than the hardness of the elastomeric coating.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Graphical user interfaces in computer-implemented multiplayer games

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Zynga Inc. patent solves the following problem:

In many online computer games, there is a virtual world or the other thought to play a place where a player with game controls one or more player characters (in characters, character player, or PCs) . Player characters can be considered in-game photos to the controlling player. As used here, the term player, users, companies, neighbors, friends, and the like can be referred to in-game player character controlled by the player, user, company, or friends, unless the context suggests otherwise. A game display can show a representation of the player character. A game engine receives inputs from the player, determine the player character, determine results of events, and presents the player with a display match ag play games. In some games, there are many players, where each player controls one or more player characters.

Our analysis of this patent is as follows:

Zynga Inc.’s patent US 9457274 B2 deals with Graphical user interfaces in computer-implemented multiplayer games.
Disclosure This generally relates to systems and methods for providing a graphical user interface to computer-implemented multiplayer game. The graphical user interface includes a panel of friends operable between a collapsed position and an expanded state. The panel's friend gave his friend information display functionality, social network management functionality, and / or messaging functionality in a collapsed state and the expanded state. A collapsed state, the panel could make friends in a bar friends who showed a row of friends cards or Chiclets associated with individual friends in a multitude of player joined an example game shows, the friends bar to clear a view of a virtual in-game environment shown in the game display, while the expanded panel could make friends in a grid with friends cards or Chiclets functionally shut the game around.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dock-and-lock (DNL) vaccines for cancer therapy

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ibc Pharmaceuticals, Inc. patent solves the following problem:

The present invention relates to the design and generation of dendritic cell-based, in vivo vaccine target for cancer therapy, such as multiple myeloma antigen. In preferred embodiments of the vaccine produced by the dock-and-lock (DNL) method, the effector moieties attached to anchor domain (AD) obtained from the AKAP protein dimerization and docking domain (DDD) moieties obtained of protein kinase a (PKA). DNL complexes generated when DDD moieties spontaneously dimerize and bind to an AD moiety, resulting in a complex with a 2: 1 stoichiometry between DDD and AD-related effectors. In more preferred embodiments, the effector moieties comprise a humanized anti-CD74 antibody, and a tumor-associated xenoantigen, such as a CD20 xenoantigen. In most preferred embodiments, the anti-CD74 antibody is an antibody hLL1. The DNL constructs for use in preparing pharmaceutical compositions, for the generation of vaccines against cancer, multiple myeloma (MM), and for the induction of an immune response against the tumor antigen expression cells, such as CD20 positive cancer cells in patients with multiple myeloma or other CD20-expressing cancers.

Our analysis of this patent is as follows:

Ibc Pharmaceuticals, Inc.’s patent US 9457072 B2 deals with Dock-and-lock (DNL) vaccines for cancer therapy.
The present invention concerns methods and compositions for the construction of the anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprising an antibody moiety that binds to dendritic cells, like an anti-CD74 antibody or antigen-binding fragment thereof, is included in an AD (anchor domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, where two copies of DDD moiety form a dimer that binds AD moiety, resulting in the formation of the DNL complicated. The anti-cancer vaccine DNL complex is able to induce an immune response against xenoantigen expressing cancer cells, as CD138negCD20 + MM stem cells and inducing apoptosis and inhibiting the growth of or eliminate cancer cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Blood clot removal device, system, and method

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Peter Forsell patent solves the following problem:

Now many implants given where the blood comes into contact with the foreign material. All of these implants have an associated risk of causing blood clots. Such clots can be loose and to make severe damage to other parts of the body. Blood clots can reach the brain is the most dangerous and regional nodules heart therefore be a priority (although not limited to) a system for blood clot removal. An example of such lumps and an example of use for clot removal system in the blood may help heart pump. If a person has heart failure, the heart can not pump enough blood to meet the needs of the body. In some cases, an advanced treatment such as a heart pump can be recommended. A heart pump takes over the function of one or both of the lower chambers of the heart, with the potential to improve your symptoms and quality of life. Once considered a last resort for prolonging life until a donor heart became available, the heart pump was a possible long-term treatment for the chosen people with heart failure .

Our analysis of this patent is as follows:

Peter Forsell’s patent US 9457172 B2 deals with Blood clot removal device, system, and method.
A blood clot removal device for getting blood clots from the vascular system of a patient Implantable patient's body. The blood clot removal device consists of a blood flow path connected to the vascular system of the patient to allow blood circulation in patients with blood flow path, a filter provided in the passage for blood collection blood clots occurring in the blood flowing through the blood flow path, and a cleaning device for removing blood clots that collected in the filter from the blood trail. Through the blood clot removal device, the risk of blood clots reach sensitive areas of the patient's body, such as brain, is reduced.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Temporarily stiffened mesh prostheses

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Tyrx, Inc. patent solves the following problem:

Artificial implants such as meshes, combined mesh products or other porous prostheses are often used to provide a physical barrier between tissue types or additional strength to a physical defects in soft tissue. However, such devices commonly associated with post-surgical complications including post-implant infection, pain, excessive scar formation and shrinkage of the prosthesis or mesh. Excessive scar formation, limited patient mobility, and chronic pain is often attributed to the size, shape, mass and implant a variety of efforts made to reduce the amount of permanent formation. For example, lighter meshes using smaller fibers, greater besieged, and / or larger size pore as he meshes woven from the -resorbable and resorbable material usage to solve these problems.

Our analysis of this patent is as follows:

Tyrx, Inc.’s patent US 9457129 B2 deals with Temporarily stiffened mesh prostheses.
The present invention relates to medical prostheses and methods of manufacturing the devices. In particular, the prostheses temporarily stiffened meshes with particular coatings provide initial hardness and thus allow easier surgical management for the treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that act as a hardening agent in the coat of filaments or fibers of the mesh in the temporary rise in points contact the filaments or fibers and / or by increasing the hardness of mesh at least 1.1 times its original hardness. In the minds of the invention may also provide relief from various post-operative complications associated with the implantation, insertion or surgical use. By including the biologically active agents and / or drugs in the coating, the devices provide Branch Tomato for relief and side effects or complications associated with the operation or use of prostheses generalized.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modified gram positive bacteria and uses thereof

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Intrexon Actobiotics Nv patent solves the following problem:

Program-positive bacteria collectively classified as a single lipid bilayer plasma membrane. Positive bacteria program includes a multitude of bacilliform and cocciform bacterial species, among which Bifidobacteria and a group of species collectively known as lactic acid bacteria (LAB). Lab consists of a Glade of gram-positive, low-GC, acid-tolerant, generally non-sporulating, non-respiring rod or cocci that are associated by their common metabolic and physiological characteristics. These bacteria, usually found in the (decomposing) plants and dairy products, lactic acid as the major metabolic end-products of carbohydrate fermentation. This character, throughout history, lab involved with food fermentations as acidification inhibits the growth of spoilage agents. A prototype Lab Lactococcus lactis is a mesophilic microaerophilic fermenting lactic acid bacteria. While the bacteria are widely used in food fermentations, especially in the dairy industry, there is an increasing interest for use in medicines and nutraceuticals, as medicine to treat infections of bodily hole as vaginal infections, or as a carrier for the delivery of biological active molecules. In all cases, there is a need for very viable starter culture, or drug or nutraceutical formulation containing a high number of viable bacteria. L. lactis, however, tends to lose viability during storage, or during processing (for ao the production of a dry powder formulation, tablet formation, …). The drop in viability more punishment when the bacteria after LYOPHILISATION submitted further pressure as high acidity or the presence of bile salts.

Our analysis of this patent is as follows:

Intrexon Actobiotics Nv’s patent US 9458467 B2 deals with Modified gram positive bacteria and uses thereof.
The present invention relates to a program positive bacteria, preferably in a lactic acid bacteria (LAB) or Bifidobacterium, with more stress resistance and / or improved manufacturing, processing and / or storage character. In particular, the invention relates to a program positive bacteria accumulate intracellular trehalose. The program positive bacteria according to the invention lacking trehalose 6-phosphate phosphorylase (TrePP) activity. The program positive bacteria becomes more than cellobiose-specific PTS system IIC component (PTCC) activity. The program positive bacteria may further overexpress trehalose transporters. invention further relates to compositions comprising the program positive bacteria as well as methods and uses thereof.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Particle separator for an air conduit, air distribution system, use of a particle separator and aircraft

File for Quick & Easy Patent Protection with PowerPatent.

The Airbus Operations Gmbh, , Diehl Aircabin Gmbh patent solves the following problem:

For the provision of a climate on board a commercial plane, climate agreeable passengers, usually an air conditioning system that uses the guiding conditioned air through a multitude of air outlets into a passenger cabin. In some cases the operating relatively high outside temperatures and a high atmospheric humidity of the surrounding air is controlled, the air conditioning packs to eject ice collected in neighboring profit system of air distribution. To prevent pressure loss in the pipes, often ice cyclically defrosted, where there is more ice accumulation can be separated from the pipe. When impacting the bottom wall of the pipe, ice accumulation decompose into small pieces and find his way as ice particles through the air outlets into the passenger cabin. The size of the ice particles estimated to be compared to the hail.

Our analysis of this patent is as follows:

Airbus Operations Gmbh, , Diehl Aircabin Gmbh’s patent US 9457303 B2 deals with Particle separator for an air conduit, air distribution system, use of a particle separator and aircraft.
A particle separator consists of a pipeline that allows a fluid to flow in a curved direction of the flow. The particle separator includes a head region, a curved deflection region, in the direction of the flow following from the mouth region, with an inside wall and an outside wall, and a delimitation body. The delimitation body at least in certain sections provided between the inner wall and the outer wall in the deflection region and curved in the same direction as the deflection region.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genmab A/S patent solves the following problem:

The EGF receptor (EGFR) is a 170 kDa type 1 transmembrane molecules. The expression found upregulated in many human tumors including carcinoma of the head and neck, breast, colon, prostate, lung, and ovaries. The kind of over-expression correlated with poor clinical prognosis (Baselga, et al (1994) Pharmac therapeut 64: ….. 127-154; Modjtahedi, et al (1994) Int J. Oncology 4: 277-296). Furthermore, his expression always accompanied by the production of EGFR ligands, TGF- and EGF among others, by EGFR-expressing tumor cells suggests that an autocrine loop participates in growth this cells (Baselga, et al. (1994) Pharmac therapeut 64: …. 127-154; Modjtahedi, et al (1994) Int J. Oncology 4: 277-296) .. Ali interaction between such EGFR ligands and EGFR therefore can inhibit tumor growth and survival (Baselga, et al (1994) Pharmac therapeut 64: 127-154).

Our analysis of this patent is as follows:

Genmab A/S’s patent US 9458236 B2 deals with Human monoclonal antibodies to epidermal growth factor receptor (EGFR).
Isolated human monoclonal antibody that specifically binds to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibody can be produced in a transfectoma or a non-human transgenic animals, for example, a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing VDJ recombination and isotype switch. also discloses pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas that produce human antibodies, and therapeutic and diagnostic methods using human antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.